BIVI Drops 50% on Bezisterim SUNRISE-PD Phase 2 Data

BioVie (BIVI) announced topline results from the Phase 2 SUNRISE-PD trial of bezisterim in early Parkinson’s disease on August 6. The stock crashed 50%, closing at $0.9993 against a $7.5 million market cap, down from roughly $2.00 before the readout. The market’s message was unambiguous: the data did not support the company’s framing.

SUNRISE-PD enrolled 57 patients with early-stage Parkinson’s who had never taken carbidopa/levodopa. Patients received 20 mg of bezisterim or placebo twice daily for 12 weeks. Bezisterim (NE3107) is an oral small molecule that crosses the blood-brain barrier and modulates NF-κB, ERK, and TNFα pathways to reduce neuroinflammation.

The study’s primary endpoint listed on ClinicalTrials.gov was change from baseline on MDS-UPDRS Part III, the standard motor exam. But the press release led with EPNIC-15, a composite of 15 motor and non-motor measures BioVie constructed itself, citing a 2025 paper on composite scales. On this composite, bezisterim showed a -0.04 change versus +0.18 for placebo (Cohen’s d = -0.94, p=0.0006).

The MDS-UPDRS Part III data, buried in a corporate presentation rather than the press release, told a different story. Placebo performed numerically better than bezisterim at lower baseline platelet counts. Bezisterim showed an advantage only in patients with higher platelet counts, roughly half the trial population, and the 95% confidence interval’s upper boundary remained above zero.

Every p-value in the release was “nominal and unadjusted for multiplicity,” meaning none were corrected for multiple comparisons. The disclaimer acknowledged the results are “exploratory” and that “the FDA has not validated these biomarkers as surrogate endpoints for Parkinson’s disease.” BioVie also filed to offer stock at $1.33 per share alongside the data release, adding to the selloff.

The biomarker data was directionally interesting. Bezisterim reduced a composite neuroinflammation measure (Cohen’s d = -1.06, p=0.0018) and lowered neurofilament light chain, a marker of neuronal damage (Cohen’s d = -0.746, p=0.008). In the high-platelet subgroup, bezisterim showed statistically significant advantages across all clinical measures. But biomarkers do not substitute for clinical endpoints, and the 57-patient, 12-week study was designed for signal-finding, not proof of disease modification.

Bezisterim’s safety profile was clean. Adverse events were reported in 39.3% of bezisterim patients versus 51.7% on placebo, with no severe or serious events and one treatment-related AE in each group. Patients on placebo had more total AEs and a higher proportion of moderate events.

The company hosts a conference call on August 12 to discuss Phase 3 design. Bezisterim is also in the ADDRESS-LC trial for Long COVID, with data expected late summer 2026. That readout is now the nearest catalyst for a company with a $7.5 million market cap.

For a framework on reading clinical trial press releases and spotting endpoint spin, see the guide to reading clinical trial press releases. For the disease-specific scoring scales behind Parkinson’s endpoints, see the guide to neuroscience clinical trial endpoints.

Source: BioVie SUNRISE-PD topline results press release, August 6, 2026 · SUNRISE-PD on ClinicalTrials.gov (NCT06757010)